Concurrent chemotherapy with hyperfractionated accelerated thoracic irradiation in stage III non-small cell lung cancer

Lochrin, C.; Goss, Glenwood D.; Cross, P.; Agboola, O.; Dahrouge, Simone; Tomiak, Eva; Evans, William K.

doi:10.1016/s0169-5002(98)00098-1

Cited by 8 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of these is the fact that response evaluation criteria varied from study to study. While some described it without any reference to existing systems [ 7 , 8 , 10 ], others used those of the Eastern Cooperative Oncology Group [ 9 ], World Health Organization [ 11 , 12 , 16 , 18 ], or cancer and Leukemia Group B [ 17 ]. It must be, however, stressed that the most recent attempt used Response and Evaluation Criteria In Solid Tumors (RECIST) more consistently, with the hope that uniformed response criteria should bring more uniformity in response reporting.…”

Section: Discussionmentioning

confidence: 99%

“…With the median survival times of 20–30 months and 5-year survivals of 25–30%, there is significant room for improvement. Various approach such as induction chemotherapy (CHT) followed by RT-CHT [ 4 , 5 ] or the addition of CHT or targeted therapy or immunotherapy after concurrent RT-ST [ 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , …”

Section: Introductionmentioning

confidence: 99%

“…Consolidation ST was seemingly first attempted some 26 years ago and has witnessed many transformations since then. During the initial years of its use, many studies used the same drugs given in both concurrent and consolidation phases of the treatment [ 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 19 , 21 , 22 , 25 , 28 , 29 , 32 , 33 , 34 , 35 , 36 , 38 , 39 , 42 , 44 , 45 , 49 , 53 , 58 , 59 , 62 , 64 , 66 , 67 , 68 , 70 ] while many subsequent studies used different drugs (“switch” approach) [ 14 , 18 , 20 , 23 , 24 , 26 , 30 , 41 , 43 , 47 , 49 , 52 , 60 , 61 ] based on the assumption that consolidation drugs may be more effective and less toxic when differ...…”

Section: Introductionmentioning

confidence: 99%

“…Regardless of the type and the number of drugs as well as the duration of the consolidation phase of the treatment, the evaluation of the patient response after the concurrent RT-ST phase of the treatment has been considered an important moment in the decision-making process, in which patients should continue the treatment with the consolidation phase [ 73 , 74 , 75 ]. While some studies did not undertake it [ 6 , 21 , 29 , 32 , 42 , 49 , 52 , 53 , 55 , 61 , 72 ], some did but continued with consolidation ST in all patients [ 7 , 8 , 11 , 15 , 16 , 17 , 18 , 19 , 20 , 30 , 31 , 37 , 38 , 40 , 44 , 45 , 48 , 51 , 56 , 59 , 60 , 62 , 66 , 67 , 68 ], while others mandated that the consolidation phase proceeds only in non-progressive disease (non-PD) patients [ 10 , 12 , 13 , 14 , 22 , 23 , 24 , 26 , 35 , 36 …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung Cancer—How to Identify Patients Which Can Benefit from It?

Jeremić

Mariamidze²,

Shoshiashvili

et al. 2022

Current Oncology

View full text Add to dashboard Cite

Background: Consolidation systemic therapy (ST) given after concurrent radiotherapy (RT) and ST (RT-ST) is frequently practiced in locally advanced inoperable nonsmall cell lung cancer (NSCLC). Little is known, however, about the fate of patients achieving different responses after concurrent phases of the treatment. Methods: we searched the English-language literature to identify full-length articles on phase II and Phase III clinical studies employing consolidation ST after initial concurrent RT-ST. We sought information about response evaluation after the concurrent phase and the outcome of these patient subgroups, the patterns of failure per response achieved after the concurrent phase as well as the outcome of these subgroups after the consolidation phase. Results: Eighty-seven articles have been initially identified, of which 20 studies were excluded for various reasons, leaving, therefore, a total of 67 studies for our analysis. Response evaluation after the concurrent phase was performed in 36 (54%) studies but in only 14 (21%) response data were provided, while in 34 (51%) studies patients underwent a consolidation phase regardless of the response. No study provided any outcome (survivals, patterns of failure) as per response achieved after the concurrent phase. Conclusions: Information regarding the outcome of subgroups of patients achieving different responses after the concurrent phase and before the administration of the consolidation phase is still lacking. This may negatively affect the decision-making process as it remains unknown which patients may preferentially benefit from the consolidation of ST.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung Cancer—How to Identify Patients Which Can Benefit from It?

Jeremić

Mariamidze²,

Shoshiashvili

et al. 2022

Current Oncology

View full text Add to dashboard Cite

show abstract

“…Lochrin et al 18 found the site of first progression to be distant metastasis and local recurrence in 41% and 44% of patients, respectively, when the patients were treated with cisplatin and vinblastine with RT. Uitterhoeve et al 5 found a 1-and 2-year local recurrence rate of 35% and 42%, respectively, using daily cisplatin and RT.…”

Section: Discussionmentioning

confidence: 99%

Five-Year Results of a Phase II Trial of Hyperfractionated Radiotherapy and Concurrent Daily Cisplatin Chemotherapy for Stage III Non-Small-Cell Lung Cancer

Keene

Harman²,

Knauf³

et al. 2005

American Journal of Clinical Oncology

View full text Add to dashboard Cite

The purpose of this study was to evaluate the 5-year results for a phase II trial of hyperfractionated radiotherapy (RT) and concurrent daily cisplatin chemotherapy. Between August 1994 and December 1999, 63 patients with stage IIIA and stage IIIB non-small-cell lung cancer were treated with RT to a dose of 69.6 Gy at 1.2 Gy twice daily with daily cisplatin at 6 mg/m. Thirty-seven patients elected to receive consolidation carboplatin and paclitaxel chemotherapy. Recurrence and survival outcomes were evaluated by Kaplan-Meier analysis. Acute and late side effects were scored by the Radiation Therapy Oncology Group (RTOG) grading system. Radiographic complete or partial tumor response was achieved in 34 of 63 (54%) of cases. Median absolute survival was 20.1 months. Median time to local recurrence and distant metastases were 10.6 and 8.6 months, respectively. Overall survival rates were 57%, 35%, and 23% at 1, 3, and 5 years, respectively. Survival was significantly greater for patients receiving consolidation chemotherapy (50% versus 20% at 3 years). Only 5 patients (7%) experienced Grade 3 or 4 esophagitis. There were 16 cases of Grade 1 or 2 pneumonitis; steroid therapy resolved symptoms in 9 patients. This regimen of hyperfractionated RT and chemotherapy achieved significant response, and 5-year survival rates with acceptable toxicity.

show abstract

Chemoradiotherapy for Inoperable Non-small Cell Lung Cancer

Cox¹

2010

Lung Cancer

View full text Add to dashboard Cite

Concurrent chemotherapy with hyperfractionated accelerated thoracic irradiation in stage III non-small cell lung cancer

Cited by 8 publications

References 33 publications

Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung Cancer—How to Identify Patients Which Can Benefit from It?

Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung Cancer—How to Identify Patients Which Can Benefit from It?

Five-Year Results of a Phase II Trial of Hyperfractionated Radiotherapy and Concurrent Daily Cisplatin Chemotherapy for Stage III Non-Small-Cell Lung Cancer

Chemoradiotherapy for Inoperable Non-small Cell Lung Cancer

Contact Info

Product

Resources

About